Nodthera To Participate In Cantor Global Healthcare Conference
Members of the NodThera management team will be available to participate in one-on-one meetings on September 10, 2026.
About NodThera
NodThera is a leading clinical-stage company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory drivers of cardiovascular and neurologic diseases driven by the NLRP3/IL-1 inflammation pathway. The Company's lead program, ruvonoflast (f/k/a NT-0796), recently completed the Phase 2 RESOLVE-1 study with topline data expected in Q3 of 2026, and expects to report results from its ongoing Phase 2 RESOLVE-2 trial in Q4 2026. The Company expects to commence a Phase 3 registrational study of ruvonoflast in H1 of 2027. The Company is also advancing trabzanoflast (f/k/a NT-0150) for treatment of neurologic diseases and expects to communicate Phase 1 topline results in Q4 of 2026.
NodThera is backed by top-tier investors including Novo Holdings, Blue Owl Capital, F-Prime Capital, 5AM Ventures, Sofinnova Partners, Epidarex Capital, and Sanofi Ventures.
NodThera is headquartered in Boston, Massachusetts, with an R&D base in the UK.
Learn more at or follow the Company on LinkedIn.
Investors and Media
Argot Partners
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment